Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
SMC (894/13)
28/05/2025
Indication
In combination with glucocorticoids for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
100mg, 500mg solution for infusion
Comments
Routinely available in line with local guidance, the paediatric licence extension, and national guidance for adults. Refer to local board guidelines for formulation details.